Val Gebski

发表

Decision models for valuing effectiveness of new diagnostic technologies

Zhixin Liu, Harold Hudson, Sarah J. Lord, 2004 .

On the issue of ‘multiple’ first failures in competing risks analysis

Val Gebski, Ian R White, David Machin, 2002, Statistics in medicine.

Multilevel latent variable models for global health‐related quality of life assessment

Jun Ma, Val Gebski, David Bulger, 2012, Statistics in medicine.

Risk of Treatment‐Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta‐analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

Val Gebski, Matthew Links, Jie Yang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The prevalence of diverticular disease in patients with slow transit constipation

Val Gebski, V. Gebski, E. Burcher, 2003, American Journal of Gastroenterology.

Audiovisual biofeedback breathing guidance for lung cancer patients receiving radiotherapy: a multi-institutional phase II randomised clinical trial

Sean Pollock, Paul J Keall, Val Gebski, 2015, BMC Cancer.

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Val Gebski, John Simes, V. Gebski, 2007, The Lancet. Oncology.

Treatment Efficacy of Sacral Nerve Stimulation in Slow Transit Constipation: A Two-Phase, Double-Blind Randomized Controlled Crossover Study

Val Gebski, Teng Zhang, Michal Szczesniak, 2015, The American Journal of Gastroenterology.

Long-Term Exposure of Eμ-Pim1 Transgenic Mice to 898.4 MHz Microwaves does not Increase Lymphoma Incidence

Val Gebski, V. Gebski, B. Vernon‐roberts, 2002, Radiation research.

Dynamic balancing randomization in controlled clinical trials

Stephane Heritier, Val Gebski, Avinesh Pillai, 2005, Statistics in medicine.

Dynamic balanced randomization for clinical trials

Val Gebski, R. J. Simes, Elaine Beller, 1993 .

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Val Gebski, Diana Zannino, M. Stockler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Val Gebski, Philipp Harter, Tomasz Huzarski, 2017, The Lancet. Oncology.

Guidelines for statistical analysis of percentage of syllables stuttered data.

Ann Packman, Mark Onslow, Val Gebski, 2006, Journal of speech, language, and hearing research : JSLHR.

EFFECT OF GLOBAL SYSTEM FOR MOBILE COMMUNICATION (GSM)‐LIKE RADIOFREQUENCY FIELDS ON VASCULAR PERMEABILITY IN MOUSE BRAIN

Val Gebski, Peter C. Blumbergs, Jim Manavis, 2001, Pathology.

Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.

Val Gebski, Jesper Grau Eriksen, Jens Overgaard, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Effect of long‐term mobile communication microwave exposure on vascular permeability in mouse brain

Val Gebski, Jim Manavis, V. Gebski, 2002, Pathology.

Predicting vitamin D deficiency in older Australian adults

Val Gebski, Alison Venn, Robyn Lucas, 2013, Clinical endocrinology.

Randomised controlled trial of the Lidcombe programme of early stuttering intervention

Ann Packman, Mark Onslow, Val Gebski, 2005, BMJ : British Medical Journal.